A study, led by HICCC members, has found that up to 20% of glioblastomas—an aggressive brain cancer—are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
In December 2020, the United States FDA authorized two approved COVID-19 vaccines. HICCC Deputy Director Gary Schwartz, MD, addresses what patients with cancer should know about the new vaccines.
Congratulations to Drs. Juan Arriaga and Jessica Hawley for winning the 2020 PCF Young Investigator Award in support of their work in prostate cancer research.
A new study by researchers in medicine and in systems biology is investigating the airway epithelium, or lining, of the lungs, to investigate potential druggable targets for COVID-19.
Research by Jacob Cogan, MD, has revealed breast cancer patients who receive mastectomy and reconstructive surgery may face risk of developing persistent use of opioids and sedative-hypnotic drugs.
Dr. Suzanne Lentzsch and her team have recently identified a promising new drug target in a subset of multiple myeloma cases, those with RAS mutations. The research was published in the journal Blood.
A physician-researcher in thoracic oncology, Dr. Catherine Shu has a focused interest in improving outcomes for lung cancer patients with resectable disease.
Seven members of the Herbert Irving Comprehensive Cancer Center (HICCC) have been named as 2020 Highly Cited Researchers by Clarivate, landing them among the most influential researchers in the world.
In breast cancer, a building body of research has revealed multitude of cancer care disparities, and patients who are among the minority underserved demographic are hit the hardest.
